PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21052690-8	2011	We found a significantly higher risk for LASM in patients carrying the caspase-1 (CASP1) 5352 A allele (RR = 2.32; 95% CI 1.22-4.42).	lasm	41-45	caspase 1	Homo sapiens	71-80
9342758-6	1997	Cytokine secretion capacity was significantly altered in LASM which exhibited reduced TNF alpha and IL-6, but elevated IL-1 alpha secretion when compared to control SM.	lasm	57-61	tumor necrosis factor	Homo sapiens	86-95
9342758-6	1997	Cytokine secretion capacity was significantly altered in LASM which exhibited reduced TNF alpha and IL-6, but elevated IL-1 alpha secretion when compared to control SM.	lasm	57-61	interleukin 6	Homo sapiens	100-104
9342758-6	1997	Cytokine secretion capacity was significantly altered in LASM which exhibited reduced TNF alpha and IL-6, but elevated IL-1 alpha secretion when compared to control SM.	lasm	57-61	interleukin 1 alpha	Homo sapiens	119-129
21052690-8	2011	We found a significantly higher risk for LASM in patients carrying the caspase-1 (CASP1) 5352 A allele (RR = 2.32; 95% CI 1.22-4.42).	lasm	41-45	caspase 1	Homo sapiens	82-87
21052690-11	2011	In conclusion, carriers of the 5352 A allele in the caspase-1 gene are at increased risk of developing LASM after SES implantation.	lasm	103-107	caspase 1	Homo sapiens	52-61